Jul 31st 2012 - Edison Investment Research today published a report on Sarepta Therapeutics entitled "Orphan Prospects". In summary, the report says:
Sarepta Therapeutics (formerly AVI BioPharma) has reported impressive initial data from a Phase IIb study with its lead product eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD), triggering a share price rise of 190%. A Phase III trial will probably be started in 2013. Despite the major re-rating of the shares, there remains further upside. There are currently limited treatments for patients with DMD, and this data also provides validation of Sarepta’s RNA-based product platform.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »